跳至主要内容
临床试验/ACTRN12616000272493
ACTRN12616000272493进行中(未招募)未知

A longitudinal, observational study investigating pigmentation genotypes and phenotypic correlations with dermoscopic naevus types and distribution in two participant groups; advanced stage melanoma patients undergoing targeted and/or immunotherapies, and a 'high risk' melanoma patient group.

The University of Queensland0 个研究点目标入组 170 人开始时间: 2016年3月1日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
170

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Cohort 1: melanoma patients with stage III and IV enrolled for treatment with targeted therapies and/or immunotherapies at the Cancer Services (PA Hospital). Baseline visit must be within 6 weeks of beginning melanoma treatment.
  • Cohort 2: participants considered high risk for melanoma under at least one of the following three subcategories;
  • a)Personal history of melanoma (stage I-IV, not in situ)
  • b)First degree family history of melanoma (stage I-IV, not in situ)
  • c)Atypical mole syndrome, defined as grater then 100 naevi, 6 (or more) atypical naevi (confirmed using dermoscopy), AND at least 1 naevus 8 mm (or greater) in dimension.

排除标准

  • All participants must be able to give informed consent.
  • All participants are asked to commit to 4 visits to the PA Hospital to participate in the trial over a 12 month period (months 0, 4, 8 and 12), as long as they are able to (Participants can withdraw from the study at any time for any reason).
  • Participants in cohort 2 must not be currently undergoing any treatment for melanoma.

研究者

相似试验